Research

Projects conducted

• Asian Treat to Target Lantus Study: Phase IV study evaluating the effectiveness and safety of  physician vs  patient led titration of insulin Glargine in type 2 diabetes mellitus (Ongoing)

• Complications in newly diagnosed diabetes in India (CINDI)
• Evaluation of safety and Efficacy of wosulin-30/70 (human Insulin Biphasic, Regular/NPH, 30:70) (rDNA origin) for control of hyperglycemia in subject with Type 2 diabetes mellitus (Phase IV Trial)
• Evaluation of efficiency and safety of Injection Detemir Phase 3 B-Clinical Trial, Trial ID: NN304-1569 (one of the five centres in the world)
• A 20-week, Multi-centre, Open-labelled, Non-comparative evaluation of the Safety and Efficacy of Insulin Detemir in Combination with OAD in Subjects with Type 2 Diabetes Inadequately Controlled on Current Therapy
• Evaluation of efficiency and safety of a fixed dose combination of MetforminXL+ Glipizide XL Vs a fixed dose combination of Metformin+ Glipizide for control of Hyperglycemia in patients with Type2 Diabetes Mellitus
• Efficacy and safety of Glipizide extended release Vs Glimipride in terms of Tolerability and Glycaemic control
• Evaluation of efficiency and safety of Gliclazide MR in people with Type 2 Diabetes Melliuts (Easy Study)
• Evaluation of efficiency and safety of Dexfenflurmine on obesity Phase IV trial
• The Durability of Twice Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine in Patients with Type 2 Diabetes and Inadequate Glycemic Control (Durability trial)
• A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose-Range Finding Study of Glucagon Inhibitor in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
• An eight week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing the safety and efficacy of Human rennin inhibitor 300 mg, 150mg, and 75 mg to ramipril 5 mg in patients with essential hypertension
• A multicenter, double-blind, randomized, active controlled study to compare the effect of 52 weeks treatment with DPP 4 inhibitor 50 mg bid to gliclazide up to 320 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin Monotherapy
• Indian Diabetic Amputation Survey

• In collaboration with -Karolinska Institute, Sweden (Noble prize fame) (Subject to permission from Govt. of India for transporting blood samples to abroad)
• Autoimmune diabetes in Elderly-prevalence and importance of recognizing it early!
• Autoimmunity in Gestational Diabetes-scope for prevention
• Diabetes in children- is it always autoimmune?
• Study of genetic markers for genetic forms of diabetes in children negative for Autoantibody markers
• Improvement of management of Type 1 D M with the help of continuous glucose monitoring + Continuous subcutaneous insulin infusion (insulin pump)
• Cell and molecular biology
• Nutrition and diet
• Islets cell transplantation and tissue culture

For Fellow Ship

All India Institute of Diabetes and Research & Yash Diabetes Specialities Centre

Invites application for
Fellowship in Diabetology Course (F. Diab)
(For MBBS+ Doctors)
Two Year Course

For application and prospectus write to the Dean of Medical Studies with Demand Draft for Rs. 500/- in favour of “All India Institute of Diabetes and Research”, payable at Ahmedabad
Swasthya Jaymangal Society, 132 feet ring road,
Naranpura, Ahmedabad 380 013, India
Phone: 079 – 2743 9977/ 7799
Fax: 079 – 2748 9977
E-Mail:diabetes@swasthyaindia.com